HAYWARD, Calif., Oct. 18 /PRNewswire-FirstCall/ -- Kosan Biosciences Incorporated will announce its third quarter 2006 financial results and highlights on Thursday, October 26, 2006, after market close.
The announcement of Kosan's third quarter 2006 financial results and highlights will be followed by a conference call and live webcast on October 26, 2006 at 1:30 p.m. Pacific / 4:30 p.m. Eastern. Interested parties may access the live call by dialing 866-831-6234 (US) or +1-617-213-8854 (international), access code 67084568.
Interested parties may listen to the webcast live at http://www.kosan.com by clicking on the "Calendar of Events" tab under the heading, "News and Events."
The webcast is also being distributed over Thomson's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through Thomson's individual investor center at http://www.earnings.com or by visiting any of the investor sites in Thomson's Individual Investor Network. Institutional investors can access the call via Thomson's password-protected event management site, StreetEvents, at http://www.streetevents.com . A telephonic replay will be available through November 2, 2006 by dialing 888-286-8010, access code: 22894235. International callers can dial +1-617-801-6888, access code: 22894235.
About Kosan
Kosan Biosciences is a biotechnology company advancing two new classes of anticancer agents through clinical development -- Hsp90 (heat shock protein 90) inhibitors and epothilones. Kosan is leveraging its proprietary discovery platform to generate a pipeline of potentially significant product candidates, primarily in the area of oncology.
Hsp90 inhibitors have a novel mechanism of action targeting multiple pathways involved in cancer cell growth and survival. Kosan's proprietary formulation of tanespimycin (KOS-953) is currently in Phase 1 and 2 clinical trials, primarily for multiple myeloma and HER2-positive breast cancer. In addition, intravenous and oral formulations of Kosan's second-generation Hsp90 inhibitor, alvespimycin (KOS-1022), are being evaluated in Phase 1 clinical trials.
Epothilones inhibit cell division with a mechanism of action similar to taxanes, one of the most successful classes of anti-tumor agents. KOS-862 is currently being studied in a Phase 2 single-agent clinical trial in patients with metastatic breast cancer, as well as a Phase 2 combination trial with Herceptin(R). KOS-1584, a second candidate designed to improve pharmacokinetics, is in Phase 1 clinical trials in patients with solid tumors. Kosan's epothilone program is partnered with Roche through a global development and commercialization agreement.
For additional information on Kosan Biosciences, please visit the company's website at www.kosan.com .
Kosan Biosciences IncorporatedCONTACT: Gary S. Titus, Chief Financial officer, +1-510-732-8400 ext.5373, or titus@kosan.com, or Jane Green, office, +1-510-731-5335, ormobile, +1-415-652-4819, or green@kosan.com, both of Kosan Biosciences
Web site: http://www.kosan.com/
